Key result
Recombinant human GH treatment initiated at age 2.4 years led to appropriate catch-up growth in a male child with isolated growth hormone deficiency type 2 caused by a novel GH1 mutation.
Why the study?
Timely diagnosis of isolated growth hormone deficiency type 2 is important for optimal recombinant human growth hormone treatment results and identifying additional pituitary deficiencies in relatives.
Case Report (n=1)
Identification of a novel GH1 mutation (c.291+2T>G) causing classical IGHD type 2, which responded appropriately to rhGH therapy.
Supports rhGH in novel GH1-related IGHD type 2; extends mutational spectrum but remains hypothesis-generating.
Isolated growth hormone (GH) deficiency (IGHD) type 2 is a rare autosomal dominant disorder characterized by severe short stature with low GH level. Timely diagnosis is important for optimal results of recombinant human GH (rhGH) treatment and detection of additional pituitary deficiencies in affected relatives. A male child presented at the age of one year with severe, proportionate short stature [-4.9 standard deviation score (SDS)] and with a normal body mass index (-1.1 SDS). Physical examination revealed frontal bossing, midfacial hypoplasia, normal external genitalia and no dysmorphic features. Paternal and maternal heights were -6.1 and -1.9 SDS. Serum insulinlike growth factor-1 (IGF-1) and IGF-binding protein-3 were undetectable and the peak GH concentration by clonidine stimulation test was extremely low (0.18 ng/mL). Brain magnetic resonance imaging showed anterior pituitary hypoplasia. Genetic analysis identified a novel heterozygous mutation (c.291+2T>G) expected to lead to splicing out exon 3 of GH1. rhGH from age 2.4 years led to appropriate catch-up. In conclusion, we identified a novel GH1 gene mutation in an infant with classical IGHD type 2 presentation.
No takes yet. Share an insight, caveat, or question.
Kautsar et al. (2019) conducted a case report in Isolated growth hormone deficiency (IGHD) type 2 (n=1). Recombinant human GH (rhGH) was evaluated on Catch-up growth. Recombinant human GH treatment initiated at age 2.4 years led to appropriate catch-up growth in a male child with isolated growth hormone deficiency type 2 caused by a novel GH1 mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: